- Home
- ALTG vs KLRS Comparison
ALTG vs KLRS Comparison
Compare ALTG & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTG
- KLRS
- Stock Information
- Founded
- ALTG 1984
- KLRS 2019
- Country
- ALTG United States
- KLRS United States
- Employees
- ALTG N/A
- KLRS N/A
- Industry
- ALTG Industrial Machinery/Components
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALTG Industrials
- KLRS Health Care
- Exchange
- ALTG Nasdaq
- KLRS Nasdaq
- Market Cap
- ALTG 119.3M
- KLRS 129.0M
- IPO Year
- ALTG N/A
- KLRS N/A
- Fundamental
- Price
- ALTG $7.78
- KLRS $2.61
- Analyst Decision
- ALTG Buy
- KLRS Buy
- Analyst Count
- ALTG 3
- KLRS 1
- Target Price
- ALTG $11.67
- KLRS N/A
- AVG Volume (30 Days)
- ALTG 344.6K
- KLRS 38.9K
- Earning Date
- ALTG 08-06-2025
- KLRS 08-15-2025
- Dividend Yield
- ALTG 2.93%
- KLRS N/A
- EPS Growth
- ALTG N/A
- KLRS N/A
- EPS
- ALTG N/A
- KLRS N/A
- Revenue
- ALTG $1,858,000,000.00
- KLRS N/A
- Revenue This Year
- ALTG $1.89
- KLRS N/A
- Revenue Next Year
- ALTG $3.09
- KLRS N/A
- P/E Ratio
- ALTG N/A
- KLRS N/A
- Revenue Growth
- ALTG N/A
- KLRS N/A
- 52 Week Low
- ALTG $3.54
- KLRS $2.28
- 52 Week High
- ALTG $11.39
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- ALTG 63.84
- KLRS N/A
- Support Level
- ALTG $6.16
- KLRS N/A
- Resistance Level
- ALTG $8.99
- KLRS N/A
- Average True Range (ATR)
- ALTG 0.45
- KLRS 0.00
- MACD
- ALTG 0.10
- KLRS 0.00
- Stochastic Oscillator
- ALTG 61.31
- KLRS 0.00
About ALTG Alta Equipment Group Inc.
Alta Equipment Group Inc is an integrated equipment dealership platform in the U.S. Its segments are Material Handling and Construction Equipment. The Material Handling segment is engaged in operations related to the sale, service, and rental of lift trucks in Michigan, Illinois, Indiana, New York, Virginia, and throughout the New England states whereas, the Construction Equipment segment is principally engaged in operations related to the sale, service, and rental of construction equipment in Michigan, Indiana, Illinois, Ohio, New York, Florida and throughout the New England States.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.